124 related articles for article (PubMed ID: 38199382)
21. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
Korpics MC; Katipally RR; Partouche J; Cutright D; Pointer KB; Bestvina CM; Luke JJ; Pitroda SP; Dignam JJ; Chmura SJ; Juloori A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):645-654. PubMed ID: 35753553
[TBL] [Abstract][Full Text] [Related]
23. Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas.
Mahase SS; Roytman M; Roth O'Brien D; Ivanidze J; Schwartz TH; Pannullo SC; Ramakrishna R; Magge RS; Williams N; Fine HA; Chiang GC; Knisely JPS
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1788. PubMed ID: 36750401
[TBL] [Abstract][Full Text] [Related]
24. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases.
McPartlin A; Swaminath A; Wang R; Pintilie M; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):388-395. PubMed ID: 28871989
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
28. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
29. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy.
Gutkin PM; Gore E; Charlson J; Neilson JC; Johnstone C; King DM; Hackbarth DA; Wooldridge A; Mannem R; Bedi M
Radiat Oncol; 2023 Mar; 18(1):42. PubMed ID: 36859309
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
[TBL] [Abstract][Full Text] [Related]
34. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases.
Kavanagh BD; Schefter TE; Cardenes HR; Stieber VW; Raben D; Timmerman RD; McCarter MD; Burri S; Nedzi LA; Sawyer TE; Gaspar LE
Acta Oncol; 2006; 45(7):848-55. PubMed ID: 16982549
[TBL] [Abstract][Full Text] [Related]
35. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
[TBL] [Abstract][Full Text] [Related]
36. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
37. Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy.
Tao C; Yang LX
Anticancer Res; 2012 Feb; 32(2):649-55. PubMed ID: 22287758
[TBL] [Abstract][Full Text] [Related]
38. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ
JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
Chmura S; Winter KA; Robinson C; Pisansky TM; Borges V; Al-Hallaq H; Matuszak M; Park SS; Yi S; Hasan Y; Bazan J; Wong P; Yoon HA; Horton J; Gan G; Milano MT; Sigurdson ER; Moughan J; Salama JK; White J
JAMA Oncol; 2021 Jun; 7(6):845-852. PubMed ID: 33885704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
